Division of Interventional Radiology, Fondazione Poliambulanza, 25124, Brescia, Italy.
Departament of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Italy.
Eur Radiol. 2021 Oct;31(10):7523-7528. doi: 10.1007/s00330-021-07930-w. Epub 2021 Apr 19.
Fusion imaging is gaining attention as an imaging technique to assist minimally invasive tumour ablation. Ultrasound (US) and computed tomography (CT) are the most common imaging modalities to guide thermal ablation of renal tumours, yet cone-beam CT (CBCT) has recently been described to successfully assist percutaneous renal interventions. Our goal was to evaluate primary technical success and correct lesion targeting of US/CBCT fusion imaging to guide the ablation of kidney masses < 2 cm in a small group of patients.
Six renal lesions (maximum diameter 11-17 mm) were treated with RFA in 5 different patients using real-time US/CBCT. Fusion imaging was used to identify and monitor tumour ablation. Demographics, tumour characteristics and mean serum creatinine levels were recorded before and after the procedure. Primary technical success and correct lesion targeting represented the main endpoints of the study. Primary technique efficacy was confirmed at 1-month and 3-month contrast-enhanced CT follow-ups.
In all cases, a confident US/CBCT synchronisation was reached and allowed for a correct targeting and a successful percutaneous ablation. Primary technique efficacy was 100%. No recurrence was observed at the follow-up that ranged from 8 to 26 months (mean 16 months).
US/CBCT fusion proved to be a viable method to precisely guide safe and effective percutaneous thermal ablation in patients with small renal tumours, especially when hardly detectable on US.
• US/CBCT fusion imaging for renal ablation is safe and feasible. • US/CBCT fusion imaging allows for an improved targeting and complete ablation of small RCC with poor US-conspicuity.
融合成像作为一种辅助微创肿瘤消融的成像技术正受到关注。超声(US)和计算机断层扫描(CT)是引导肾肿瘤热消融最常用的成像方式,但最近已描述锥形束 CT(CBCT)可成功协助经皮肾介入。我们的目标是在一小部分患者中评估 US/CBCT 融合成像引导肾肿块 <2cm 消融的主要技术成功率和正确的病变定位。
5 例不同患者的 6 个肾肿瘤(最大直径 11-17mm)采用 RFA 治疗。实时 US/CBCT 用于识别和监测肿瘤消融。记录治疗前后的患者人口统计学、肿瘤特征和平均血清肌酐水平。主要技术成功率和正确的病变定位是本研究的主要终点。主要技术疗效在 1 个月和 3 个月的增强 CT 随访中得到确认。
所有病例均成功实现了有信心的 US/CBCT 同步,从而实现了正确的定位和成功的经皮消融。主要技术疗效为 100%。在 8 至 26 个月(平均 16 个月)的随访中未观察到复发。
US/CBCT 融合被证明是一种可行的方法,可精确指导小肾癌患者安全有效的经皮热消融,特别是当 US 几乎无法检测到时。
• 用于肾消融的 US/CBCT 融合成像安全可行。
• US/CBCT 融合成像可改善对 US 显影不佳的小 RCC 的靶向和完全消融。